Juan J Badimon

Quick facts

Marketed products

• Clopidogrel + ASA + Bivalirudin · Cardiovascular
  This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events.
• Ticagrelor + ASA + Bivalirudin · Cardiovascular
  This combination uses ticagrelor and aspirin to inhibit platelet aggregation via P2Y12 and COX-1 pathways, while bivalirudin provides direct thrombin inhibition to prevent thrombotic events.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Juan J Badimon portfolio CI brief
• Juan J Badimon pipeline updates RSS